These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 22456116)

  • 1. Clinical significance of serum decoy receptor 3 levels in patients with systemic sclerosis.
    Yamada D; Asano Y; Takahashi T; Masui Y; Aozasa N; Akamata K; Noda S; Tamaki Z; Tada Y; Sugaya M; Sato S; Kadono T
    Eur J Dermatol; 2012; 22(3):351-7. PubMed ID: 22456116
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Serum levels of galectin-3: possible association with fibrosis, aberrant angiogenesis, and immune activation in patients with systemic sclerosis.
    Taniguchi T; Asano Y; Akamata K; Noda S; Masui Y; Yamada D; Takahashi T; Ichimura Y; Toyama T; Tamaki Z; Tada Y; Sugaya M; Kadono T; Sato S
    J Rheumatol; 2012 Mar; 39(3):539-44. PubMed ID: 22247367
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Association of C-reactive protein with high disease activity in systemic sclerosis: results from the Canadian Scleroderma Research Group.
    Muangchan C; Harding S; Khimdas S; Bonner A; ; Baron M; Pope J
    Arthritis Care Res (Hoboken); 2012 Sep; 64(9):1405-14. PubMed ID: 22556030
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical significance of serum retinol binding protein-4 levels in patients with systemic sclerosis.
    Toyama T; Asano Y; Takahashi T; Aozasa N; Akamata K; Noda S; Taniguchi T; Ichimura Y; Sumida H; Tamaki Z; Masui Y; Tada Y; Sugaya M; Sato S; Kadono T
    J Eur Acad Dermatol Venereol; 2013 Mar; 27(3):337-44. PubMed ID: 22211766
    [TBL] [Abstract][Full Text] [Related]  

  • 5. High intestinal and systemic levels of decoy receptor 3 (DcR3) and its ligand TL1A in active ulcerative colitis.
    Bamias G; Kaltsa G; Siakavellas SI; Papaxoinis K; Zampeli E; Michopoulos S; Zouboulis-Vafiadis I; Ladas SD
    Clin Immunol; 2010 Nov; 137(2):242-9. PubMed ID: 20675196
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical significance of serum soluble Tie1 levels in patients with systemic sclerosis.
    Noda S; Asano Y; Aozasa N; Akamata K; Taniguchi T; Takahashi T; Ichimura Y; Toyama T; Sumida H; Kuwano Y; Yanaba K; Tada Y; Sugaya M; Kadono T; Sato S
    Arch Dermatol Res; 2013 May; 305(4):325-31. PubMed ID: 23233281
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Serum levels of interleukin-18-binding protein isoform a: Clinical association with inflammation and pulmonary hypertension in systemic sclerosis.
    Nakamura K; Asano Y; Taniguchi T; Minatsuki S; Inaba T; Maki H; Hatano M; Yamashita T; Saigusa R; Ichimura Y; Takahashi T; Toyama T; Yoshizaki A; Miyagaki T; Sugaya M; Sato S
    J Dermatol; 2016 Aug; 43(8):912-8. PubMed ID: 26777734
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Rheumatoid factor isotypes and anti-agalactosyl IgG antibodies in systemic sclerosis.
    Mimura Y; Ihn H; Jinnin M; Asano Y; Yamane K; Yazawa N; Tamaki K
    Br J Dermatol; 2004 Oct; 151(4):803-8. PubMed ID: 15491420
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Serum levels of interleukin 6 (IL-6), oncostatin M, soluble IL-6 receptor, and soluble gp130 in patients with systemic sclerosis.
    Hasegawa M; Sato S; Fujimoto M; Ihn H; Kikuchi K; Takehara K
    J Rheumatol; 1998 Feb; 25(2):308-13. PubMed ID: 9489824
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Increased serum pentraxin 3 in patients with systemic sclerosis.
    Iwata Y; Yoshizaki A; Ogawa F; Komura K; Hara T; Muroi E; Takenaka M; Shimizu K; Hasegawa M; Fujimoto M; Takehara K; Sato S
    J Rheumatol; 2009 May; 36(5):976-83. PubMed ID: 19273457
    [TBL] [Abstract][Full Text] [Related]  

  • 11. DcR3 as a diagnostic parameter and risk factor for systemic lupus erythematosus.
    Han B; Bojalil R; Amezcua-Guerra LM; Springall R; Valderrama-Carvajal H; Wu J; Luo H
    Int Immunol; 2008 Aug; 20(8):1067-75. PubMed ID: 18562337
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dynamics of serum angiopoietin-2 levels correlate with efficacy of intravenous pulse cyclophosphamide therapy for interstitial lung disease associated with systemic sclerosis.
    Takahashi T; Asano Y; Akamata K; Aozasa N; Taniguchi T; Noda S; Masui Y; Ichimura Y; Toyama T; Tamaki Z; Tada Y; Sugaya M; Kadono T; Sato S
    Mod Rheumatol; 2013 Sep; 23(5):884-90. PubMed ID: 22972016
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical significance of soluble CD31 in patients with systemic sclerosis (SSc): association with limited cutaneous SSc.
    Sato S; Komura K; Hasegawa M; Fujimoto M; Takehara K
    J Rheumatol; 2001 Nov; 28(11):2460-5. PubMed ID: 11708419
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Serum levels of ADAM12-S: possible association with the initiation and progression of dermal fibrosis and interstitial lung disease in patients with systemic sclerosis.
    Taniguchi T; Asano Y; Akamata K; Aozasa N; Noda S; Takahashi T; Ichimura Y; Toyama T; Sumida H; Kuwano Y; Yanaba K; Tada Y; Sugaya M; Kadono T; Sato S
    J Eur Acad Dermatol Venereol; 2013 Jun; 27(6):747-53. PubMed ID: 22540429
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Increased circulating soluble vascular adhesion protein-1 levels in systemic sclerosis: association with lower frequency and severity of interstitial lung disease.
    Yanaba K; Yoshizaki A; Muroi E; Ogawa F; Shimizu K; Sato S
    Int J Rheum Dis; 2013 Aug; 16(4):442-7. PubMed ID: 23992266
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Anti-DNA topoisomerase II alpha autoantibodies in Japanese patients with systemic sclerosis.
    Hayakawa I; Hasegawa M; Takehara K; Sato S
    Arch Dermatol Res; 2005 Oct; 297(4):180-3. PubMed ID: 16180014
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Determinants of morbidity and mortality of systemic sclerosis in Canada.
    Al-Dhaher FF; Pope JE; Ouimet JM
    Semin Arthritis Rheum; 2010 Feb; 39(4):269-77. PubMed ID: 18706680
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Elevated serum levels of interleukin 4 (IL-4), IL-10, and IL-13 in patients with systemic sclerosis.
    Hasegawa M; Fujimoto M; Kikuchi K; Takehara K
    J Rheumatol; 1997 Feb; 24(2):328-32. PubMed ID: 9034992
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of Bosentan on systemic sclerosis-associated interstitial lung disease ineligible for cyclophosphamide therapy: a prospective open-label study.
    Furuya Y; Kuwana M
    J Rheumatol; 2011 Oct; 38(10):2186-92. PubMed ID: 21885489
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical significance of surfactant protein D as a serum marker for evaluating pulmonary fibrosis in patients with systemic sclerosis.
    Asano Y; Ihn H; Yamane K; Yazawa N; Kubo M; Fujimoto M; Tamaki K
    Arthritis Rheum; 2001 Jun; 44(6):1363-9. PubMed ID: 11407696
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.